en · de · es · fr · pt
tirzepatide-notes.peptides1004.com › Info › Tirzepatide �ˆ†子背景与靶点 — Worked Examples

Tirzepatide �ˆ†子背景与靶点 — Worked Examples

By Editorial Desk · published 2025-11-17 · last reviewed 2025-12-09 · Info

GLP-1 receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-12-09. Anything still debated is marked as such rather than presented as settled.

Tirzepatide 分子背景与靶点

脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强,从而延长循环半衰期,支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征,减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用,属于既定的药代动力学策略。

该化合物的名称与结构由国际非专利名称体系统一维持,不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

Background And Receptor Pharmacology

Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.

Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.

Tirzepatide at a glance

PropertyValueNotes
分子类型合成修饰肽39 个氨基酸,含脂肪酸侧链
受体靶点GIP 与 GLP-1 受体双重激动剂
分子量约 4.8 kDa以游离肽计
外观白色至类白色粉末冻干形态常见
溶解性可溶于水及水性缓冲液溶解后宜低温保存

Analytical Methods, Stability and Verification

Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.

Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.

Related pages on this site

Analytical Characterisation and Storage Practice

Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.

Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.

Tirzepatide Pharmacology and Development History

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Further detail

Pure obsidian is usually dark in appearance, though the color varies depending on the impurities present. Iron and other transition elements may give the obsidian a dark brown to black color. Most black obsidians contain nanoinclusions of magnetite, an iron oxide. Very few samples of obsidian are nearly colorless. In some stones, the inclusion of small, white, radially clustered crystals (spherulites) of the mineral cristobalite in the black glass produce a blotchy or snowflake pattern (snowflake obsidian). Obsidian may contain patterns of gas bubbles remaining from the lava flow, aligned along layers created as the molten rock was flowing before being cooled. These bubbles can produce interesting effects such as a golden sheen (sheen obsidian). An iridescent, rainbow-like sheen (fire obsidian) is caused by inclusions of magnetite nanoparticles creating thin-film interference. Colorful, striped obsidian (rainbow obsidian) from Mexico contains oriented nanorods of hedenbergite, which cause the rainbow striping effects by thin-film interference.

== Function == Because NADP(H), which exists in oxidized (NADP+) and reduced (NADPH) forms, cannot cross the mitochondrial membrane, eukaryotic cells maintain separate cytosolic and mitochondrial NADP(H) pools through dedicated NAD kinases. In mitochondria, NADK2 catalyzes the phosphorylation of NAD+ to NADP+ and, notably, can also phosphorylate NADH to NADPH. NADP+ generated by NADK2 or by NADPH oxidation is reduced to NADPH by enzymes including NNT, GLUD1, ME2, ALDH1L2, and IDH2. By contrast, using NADH as a substrate allows NADK2 to generate mitochondrial NADPH directly and rapidly, albeit at the expense of ATP. These reactions maintain a predominantly reduced NADPH pool that provides electrons for central mitochondrial processes. As mitochondria are a major source of oxidative stress due to reactive oxygen species (ROS) generated by the electron transport chain, they depend on NADPH for antioxidant protection. Mitochondrial NADPH fulfills this role by regenerating glutathione and thioredoxin via glutathione reductase and thioredoxin reductase, respectively, thereby supporting the detoxification of ROS. NADPH also fuels mitochondrial fatty acid synthesis (mtFAS) through enzymes such as MECR, contributing to protein lipoylation as well as mitochondrial translation, electron transport chain assembly, and citric acid cycle function.

Prior to the outbreak of the civil war in 1991, the roughly 53 state-owned small, medium and large manufacturing firms were foundering, with the ensuing conflict destroying many of the remaining industries. However, primarily as a result of substantial local investment by the Somali diaspora, many of these small-scale plants have reopened and newer ones have been created. The latter include fish-canning and meat-processing plants in the northern regions, as well as about 25 factories in the Mogadishu area, which manufacture pasta, mineral water, confections, plastic bags, fabric, hides and skins, detergent and soap, aluminium, foam mattresses and pillows, fishing boats, carry out packaging, and stone processing. In 2004, a US$8.3 million Coca-Cola bottling plant also opened in the city, with investors hailing from various constituencies in Somalia. Foreign investment also included multinationals including General Motors and Dole Fruit.

The balance-of-power system is discredited today. References to it, even by professional historians and international lawyers, commonly imply either that it was a system for war which repeatedly failed or that it was a system for making war which often succeeded in its purpose … During the period of its dominance as a European system, say, 1648 to 1918, its record in preventing war was certainly not striking. Indeed, it probably was itself responsible for starting more wars than it prevented. Former German Foreign Minister Joschka Fischer interpreted the core of the concept of Europe after 1945 as the rejection of the European balance-of-power principle and the hegemonic ambitions of individual states that had emerged following the Peace of Westphalia in 1648: "European integration was the response to centuries of a precarious balance of powers on this continent which again and again resulted in terrible hegemonic wars and culminated in the two World Wars between 1914 and 1945." Former US Secretary of Defense Dick Cheney expressed the same for Europe and other democracies: "It is not in our interest or those of the other democracies to return to earlier periods in which multiple military powers balanced one against another in what passed for security structures, while regional, or even global peace hung in the balance." NATO Secretary General, Manfred Wörner, outlined the European alternative at the end of the Cold War:

=== Development === The first human clinical trial using ex vivo dendritic cells transfected with mRNA encoding tumor antigens (therapeutic cancer mRNA vaccine) was started in 2001. Four years later, the successful use of modified nucleosides as a method to transport mRNA inside cells without setting off the body's defense system was reported. Clinical trial results of an mRNA vaccine directly injected into the body against cancer cells were reported in 2008. BioNTech in 2008, and Moderna in 2010, were founded to develop mRNA biotechnologies. The US research agency DARPA launched at this time the biotechnology research program ADEPT to develop emerging technologies for the US military. The agency recognized the potential of nucleic acid technology for defense against pandemics and began to invest in the field. DARPA grants were seen as a vote of confidence that in turn encouraged other government agencies and private investors to invest in mRNA technology. DARPA awarded at the time a $25 million grant to Moderna. The first human clinical trials using an mRNA vaccine against an infectious agent (rabies) began in 2013. Over the next few years, clinical trials of mRNA vaccines for a number of other viruses were started. mRNA vaccines for human use were studied for infectious agents such as influenza, Zika virus, cytomegalovirus, and Chikungunya virus.

Sources: en.wikipedia.org

Supporting material

== Medical usage == Sermorelin was used to treat children with growth hormone deficiency or growth failure by stimulating the pituitary gland to release growth hormone (GH), thereby increasing plasma GH levels.

== References == This article was adapted from the following source under a CC BY 4.0 license (2019) (reviewer reports): Stephen Branden Van Oss; Anne-Ruxandra Carvunis (2019). "De novo gene birth". PLOS Genetics. 15 (5) e1008160. doi:10.1371/journal.pgen.1008160. PMC 6542195. PMID 31120894. Wikidata Q86320144.

=== Psychology === The psychological studies Body Image Concerns of Breast Augmentation Patients (2003) and Body Dysmorphic Disorder and Cosmetic Surgery (2006) indicate that women who seek breast-augmentation surgery usually have a mental-health background that features treatments of psychotherapy, who suffer many occurrences low self-esteem and of psychological depression, in comparison with the general population of women. Moreover, women who sought breast augmentation also suffered body dysmorphia, which is an extreme dissatisfaction and preoccupation with perceived physical defects in her personal appearance, which misperceptions often lead to significant impairment of her mental ability to function socially. Post-operative patient surveys about the mental health and the quality of life of the women, reported improved physical health, physical appearance, social life, self-confidence, self-esteem, and satisfaction with sexual functioning. Furthermore, most of the women reported long-term satisfaction with their breast implants; some despite having had medical complications that required surgical revision, either corrective or aesthetic. In Denmark, 8.0 percent of breast augmentation patients had a pre-operative history of psychiatric hospitalization.

== History == DESI has been widely studied since its inception in 2004 by Zoltan Takáts, Justin Wiseman and Bogdan Gologan, in Graham Cooks' group from Purdue University with the goal of looking into methods that didn't require the sample to be inside of a vacuum. Both DESI and direct analysis in real time (DART) have been largely responsible for the rapid growth in ambient ionization techniques, with a proliferation of more than eighty new techniques being found today. These methods allow for complex systems to be analyzed without preparation and throughputs as high as 45 samples a minute. DESI is a combination of popular techniques, such as, electrospray ionization and surface desorption techniques. Electrospray ionization with mass spectrometry was reported by Malcolm Dole in 1968, but John Bennett Fenn was awarded a nobel prize in chemistry for the development of ESI-MS in the late 1980s. Then in 1999, desorption of open surface and free matrix experiments were reported in the literature utilizing an experiment that was called desorption/ionization on silicon. The combination of these two advancements led to the introduction of DESI and DART as the main ambient ionization techniques that would later become multiple different techniques. One in particular, due to increasing studies into optimization of DESI, is nanospray desorption electrospray ionization (nano-DESI). In this technique the analyte is desorbed into a liquid bridge formed between two capillaries and the analysis surface.

Sources: en.wikipedia.org

Notes from published material

Early phlebotomists used techniques such as leeches and incision to extract blood from the body. Bloodletting was used as a therapeutic as well as a prophylactic process, thought to remove toxins from the body and to balance the humors. While physicians did perform bloodletting, it was a specialty of barber surgeons, the primary provider of health care to most people in the medieval and early modern eras.

Brain natriuretic peptide (BNP), also known as B-type natriuretic peptide, is a peptide hormone secreted by cardiomyocytes in the heart ventricles in response to stretching caused by increased ventricular blood volume. BNP is one of the three natriuretic peptides, in addition to atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). BNP was first discovered in porcine brain tissue in 1988, which led to its initial naming as "brain natriuretic peptide", although subsequent research revealed that BNP is primarily produced and secreted by the ventricular myocardium (heart muscle) in response to increased ventricular blood volume and stretching. To reflect its true source, BNP is now often referred to as "B-type natriuretic peptide" while retaining the same acronym. The 32-amino acid polypeptide BNP-32 is secreted attached to a 76–amino acid N-terminal fragment in the prohormone called NT-proBNP (BNPT), which is biologically inactive. Once released, BNP binds to and activates the atrial natriuretic factor receptor NPRA, and to a lesser extent NPRB, in a fashion similar to atrial natriuretic peptide (ANP) but with 10-fold lower affinity. The biological half-life of BNP, however, is twice as long as that of ANP, and that of NT-proBNP is even longer, making these peptides better targets than ANP for diagnostic blood testing. The physiologic actions of BNP are similar to those of ANP and include decrease in systemic vascular resistance and central venous pressure as well as an increase in natriuresis.

Opipramol acts as a high affinity sigma receptor agonist, primarily of the σ1 subtype, but also of the σ2 subtype with lower affinity. In one study of σ1 receptor ligands that also included haloperidol, pentazocine, (+)-3-PPP, ditolylguanidine, dextromethorphan, SKF-10,047 ((±)-alazocine), ifenprodil, progesterone, and others, opipramol showed the highest affinity (Ki = 0.2–0.3) for the guinea pig σ1 receptor of all the tested ligands except haloperidol, which it was approximately equipotent with. The sigma receptor agonism of opipramol is thought to be responsible for its therapeutic benefits against anxiety and depression. Unlike other TCAs, opipramol does not inhibit the reuptake of serotonin or norepinephrine. However, it does act as a high affinity antagonist of the histamine H1 receptor and is a low to moderate affinity antagonist of the dopamine D2, serotonin 5-HT2, and α1-adrenergic receptors. H1 receptor antagonism accounts for its antihistamine effects and associated sedative side effects. In contrast to other TCAs, opipramol has very low affinity for the muscarinic acetylcholine receptors and virtually no anticholinergic effects. Sigma receptors are a set of proteins located in the endoplasmic reticulum. σ1 receptors play key role in potentiating intracellular calcium mobilization thereby acting as sensor or modulator of calcium signaling. Occupancy of σ1 receptors by agonists causes translocation of the receptor from endoplasmic reticulum to peripheral areas (membranes) where the σ1 receptors cause neurotransmitter release.

Reform UK announces plans to cut government spending by £20bn a year if elected to government, with their plans including removing the right to claim benefits from EU citizens. 19 November – BBC News suggests that Labour MP Clive Lewis offered to give up his Norwich South constituency to allow Andy Burnham to return to the House of Commons, paving the way for Burnham to challenge Keir Starmer for the party's leadership, although they also say that Lewis later told The Sun that he had "no plans to stand down". Laura Anne Jones is suspended from the Senedd chamber for 14 days for breaking the parliamentary code over her use of a racial slur in a WhatsApp message. The Guardian reports allegations that, as a child almost 50 ago, Reform's Nigel Farage made anti-Semitic comments and taught younger pupils at Dulwich College racist songs. The paper also reports that other former pupils who know Farage said that they do not recall the behaviour described. Farage denied making any of the comments that were attributed to him. Andrew Polson, the former leader of Dunbartonshire Council, is sentenced to 22 months in prison for a £188,000 romance fraud. 20 November – COVID-19 in the UK: The second report to be released by the COVID-19 Inquiry summarises the UK's response to the pandemic as "too little, too late", and says lockdown may have been unnecessary if steps such as social distancing and the isolation of those with symptoms along with members of their household had been brought in earlier than mid-March 2020. Former Labour MP Lloyd Russell-Moyle defects to the Greens.

On 16 January 2023 an Italian court approved the extradition of Silvia Panzeri, daughter of Pier Antonio. In January 2023 Panzeri pleaded guilty to his part of the conspiracy as part of a plea deal with the Belgian authorities. As part of the deal Panzeri will reveal the identities of those he bribed as well as those he conspired with. It is foreseen he will receive a sentence of five years of which four would be suspended. The remaining year would be served in prison or with an electronic bracelet, or a combination of both. This was only the second time that Belgian prosecutors have made a plea deal as they were previously not permissible in law. The German magazine Der Spiegel was given access to over 1,300 documents from the Belgian investigation. According to these documents, Panzeri's group received payment in cash from Qatar, Morocco, Mauritania and possibly Saudi Arabia. The group are described as "shockingly amateurish", because they stored the money they received in bribes in their apartments, made hundreds of unencrypted telephone calls and held a "conspiratorial meeting in a hotel that was full of surveillance cameras". Nevertheless, they operated undetected for years. A spreadsheet found on one computer lists 199 meetings and activities undertaken by a number of named people between April 2018 and December 2022.

Sources: en.wikipedia.org

Frequently asked questions

Tirzepatide 属于哪一类分子?

它属于合成修饰肽,同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂,与选择性 GLP-1 激动剂在靶点范围上不同。

为什么它只需每周给药一次?

分子上的脂肪酸侧链使其与血浆白蛋白结合增强,显著延长循环半衰期。半衰期延长后,稳定血药浓度可在较长的给药间隔内维持,因此常见用法为每周一次。

双靶点设计的意义是什么?

同时激活两条肠促胰素通路可能在胰岛素分泌、胃排空和食欲调节上产生叠加效应。与单靶点相比,临床研究中观察到的血糖与体重变化幅度通常更明显,但各通路的具体贡献比例尚无定论。

What is tirzepatide?

It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.

Network